Trial Profile

A Phase 2/3, Randomized, Double Blind, Placebo Controlled, Multicenter Study to Evaluate the Efficacy and Safety of FP-025 in Patients With Severe to Critical COVID 19 With Associated Acute Respiratory Distress Syndrome (ARDS)

Status: Discontinued

Phase of Trial: Phase II/III

Latest Information Update: 09 Jan 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs FP 025 (Primary)
Indications Adult respiratory distress syndrome; COVID-19 respiratory infection
Focus Therapeutic Use
Sponsors Foresee Pharmaceuticals

31 May 2022 According to a Foresee Pharmaceuticals media release, phase 2 results are expected in 2H 2022.
19 Apr 2022 Status changed from recruiting to discontinued.
28 Apr 2021 Planned End Date changed from 1 Aug 2022 to 1 Feb 2022.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com